Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema
Graefe's Archive for Clinical and Experimental Ophthalmology, Volume 251, No. 7, Year 2013
Notification
URL copied to clipboard!
Description
Purpose: To evaluate the efficacy of bromfenac drops alone or with a single intravitreal injection of bevacizumab (IVB) or triamcinolone acetonide (IVTA) in the treatment of uveitic macular edema (UME). Design: Comparative case series. Study Participant: Sixty-seven eyes (of 55 patients) with UME that received either bromfenac drops alone (n = 34), IVB plus bromfenac (n = 21) or IVTA plus bromfenac (n = 12). Methods: Chart review of patients at the Massachusetts Eye Research and Surgery Institution (MERSI) was done. Eyes that received either bromfenac drops alone (Br), IVB plus bromfenac (IVB/Br) or IVTA plus bromfenac (IVTA/Br), with follow-up of up to 3 months, were included. Main Outcome Measure: Visual acuity. Results: There was no statistically significant effect seen in VA or CMT in the Br group, with 17 of 34 eyes (50 %) needing re-injection before 3 months of follow-up. Mean change in CMT at 4 weeks for the Br group was 5.06 μm. Compared to baseline, both the IVTA/Br and IVB/Br groups showed significant decrease in CMT and improvement in VA at 1 and 3 months follow-up. There was also a continuous decrease in CMT up to 3 months of follow-up with the IVTA/Br group, which was found to be significant in comparison with the IVB/Br group; this trend was not seen in the IVB/Br group at 3 months. The greatest mean change in CMT at 1 month was seen in the IVTA/Br group (154.33 ±178.22 μm), and this was statistically significant in comparison with the other groups (p = <0.0001). However, in terms of mean change in VA, there was no change in the Br group (0.01 ± 0.11 VA logMAR), and only 0.12 ± 0.19 and 0.15 ± 0.20 in the IVB/Br and IVTA/Br groups, respectively. Conclusion: IVB and IVTA are both effective in improving VA and decreasing CMT up to 3 months. Bromfenac is ineffective alone for UME treatment, but may have a synergistic effect with IVTA in reducing CMT up to 3 months of follow-up. © 2013 Springer-Verlag Berlin Heidelberg.
Authors & Co-Authors
Radwan, Alaa E.
United States, Cambridge
Massachusetts Eye Research and Surgery Institution
United States, Cambridge
The Ocular Immunology and Uveitus Foundation
Arcinue, Cheryl A.
United States, Cambridge
Massachusetts Eye Research and Surgery Institution
United States, Cambridge
The Ocular Immunology and Uveitus Foundation
Yang, Paul
United States, Cambridge
Massachusetts Eye Research and Surgery Institution
United States, Cambridge
The Ocular Immunology and Uveitus Foundation
Artornsombudh, Pichaporn
United States, Cambridge
Massachusetts Eye Research and Surgery Institution
United States, Cambridge
The Ocular Immunology and Uveitus Foundation
Alfadl, Esam Abu
Egypt, Sohag
Faculty of Medicine
Foster, Charles Stephen
United States, Cambridge
Massachusetts Eye Research and Surgery Institution
United States, Cambridge
The Ocular Immunology and Uveitus Foundation
United States, Boston
Harvard Medical School
Statistics
Citations: 29
Authors: 6
Affiliations: 4
Identifiers
Doi:
10.1007/s00417-013-2309-4
ISSN:
0721832X
e-ISSN:
1435702X
Research Areas
Health System And Policy
Study Design
Cohort Study